Tag: Leadiant

AMSTERDAM: The Pharmaceutical Accountability Foundation (PAF), a group of legal and medical experts and public health advocates, today welcomes the news that the Spanish competition authority CNMC has fined pharmaceutical company Leadiant €10.25 million for its abuse of its market position to overcharge sufferers of a rare genetic disease. Apart...

As an international student I have always sought out opportunities to meet local people and to broaden my personal and professional network. When provided with the occasion, I did not hesitate to write my master's thesis in partnership with the Pharmaceutical Accountability Foundation as I was sure it would be...

Bergeijk, June 2, 2022 The Italian Competition Authority (ICA) decided on 31 May that pharmaceutical company Leadiant has charged the Italian National Health Service excessive prices for the life-saving medicine Chenodeoxycholic acid (CDCA), and issued a fine of €3.5million.  “We believe that pharmaceutical companies have a duty of care to make...

On 27 January we hosted the second part of our webinar series The Power of Law. This second part was dedicated to presenting our recently published Guidelines for Legal Procedures by NGOs, which we illustrated with examples from practice. Missed the webinar or want to listed back a part...

On 17 november, Wilbert Bannenberg, chair of the Pharmaceutical Accountability Foundation, presented at the regional Access to Medicines Dialogue of the EU Alliance. The dialogue is organized by the International Treatment Preparedness Coalition (ITPC) and hosted by the European Alliance for Responsible R&D and Affordable Medicines. Wilbert was invited as...

Bergeijk, July 19, 2021 On September 7, 2018, the Pharmaceutical Accountability Foundation (PAF) submitted an enforcement request  for abuse of a dominant market position by the company Leadiant with the drug CDCA. The company had increased the price 500 fold after obtaining orphan drug market exclusivity. The Netherlands Authority for...

The Pharmaceutical Accountability Foundation welcomes the news that the Amsterdam UMC (Amsterdam University Medical Centers) has resumed supplying Dutch patients with the rare disease Cerebrotendinous Xanthomathosis (CTX) with pharmacy compounded chenodeoxycholic acid (CDCA). This action became necessary after Leadiant Biosciences had increased the price of one CDCA capsule from €0,28...